Summary
1,2,3,4-Tetrahydro-1,1,4,4-tetramethyl-y-[(E)-alpha-methylstyryl]-naphtalene (Ro 15-0778), a potent inhibitor of sebaceous gland activity in several animal models has been administered to male volunteers in dosages of 1, 2, 3, and 6 mg/kg/day and 2 g/day for 8 weeks. Sebum production was measured before treatment and after 4 and 8 weeks of therapy. At the dosage levels of 1,2,3, and 6 mg/kg/day there was no decrease in sebum secretion. With the dosage of 2 g/day, a significant decrease in sebum secretion was seen after 8 weeks of treatment with Ro 15-0778.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Boris A, Hurley JF, Comai K, Shapiro SS (1987) Antisebum and endocrine properties of Ro 15-0778. J Invest Dermatol 88:478
Harris HH, Downing DT, Stewart ME, Strauss JS (1983) Sustainable rates of sebum secretion in acne patients and matched normal control subjects. J Am Acad Dermatol 8:200–203
Vane FM, Chari SS, Hurley JF, Shapiro SS, Nordstrom KM, Leyden JJ (1987) Concentrations of the sebum-suppressing agent, Ro 15-0778, in tissues of test animals and acne patients. J Invest Dermatol 88:522
Author information
Authors and Affiliations
Additional information
Supported in part by a grant from Hoffmann-LaRoche, Nutley, NJ, and by US Public Health Service Grant AR 22083
Rights and permissions
About this article
Cite this article
Strauss, J.S., Davey, W.P., Denton, S.J. et al. Effect of an orally administered arotinoid, Ro 15-0778, on sebum production in man. Arch Dermatol Res 280, 152–154 (1988). https://doi.org/10.1007/BF00456845
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00456845